GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Pubmed ID: 30930049
Publication Date: 2019/03/28

Inhibition of the MET Kinase Activity and Cell Growth in MET-Addicted Cancer Cells by Bi-Paratopic Linking.

MET, the product of the c-MET proto-oncogene, and its ligand hepatocyte growth factor/scatter factor (HGF/SF) control survival, proliferation and migration during development and tissue regeneration. HGF/SF-MET signaling is equally crucial for growth and metastasis of a variety of human tumors, but resistance to small-molecule inhibitors of MET kinase develops rapidly and therapeutic antibody targeting remains challenging. We made use of the designed ankyrin repeat protein (DARPin) technology to develop an alternative approach for inhibiting MET. We generated a collection of MET-binding DARPins covering epitopes in the extracellular MET domains and created comprehensive sets of bi-paratopic fusion proteins. This new class of molecules efficiently inhibited MET kinase activity and downstream signaling, caused receptor downregulation and strongly inhibited the proliferation of MET-dependent gastric carcinoma cells carrying MET locus amplifications. MET-specific bi-paratopic DARPins may represent a novel and potent strategy for therapeutic targeting of MET and other receptors, and this study has elucidated their mode of action.
Authors: Andres Fabio , Iamele Luisa , Meyer Timo , Stüber Jakob C , Kast Florian , Gherardi Ermanno , Niemann Hartmut H , Plückthun Andreas ,


  1. [Last access 2019/03/28].

Related products :

Catalog number Product name Quantity
30-121 C21orf33 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggests that growth inhibition induced in these cells by all-trans retinoic acid occurs via 0.1 mg
orb60096 STF-62247 Targeting VHL-deficient RCC cells, in renal cell carcinoma (RCC) cells that have lost the von Hippel-Lindau (VHL) tumor suppressor activity (IC50 = 625 5 mg
2-96038 Human Cancer PrimaCell™15: Skin Cancer Cells, primary cell culture Kit
9-80038 Human Cancer PrimaCell™15: Skin Cancer Cells, primary cell culture 1 x 100 ml
9-47038 Human Cancer PrimaCell™15: Skin Cancer Cells, primary cell culture set